209 related articles for article (PubMed ID: 36996217)
1. Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.
Mukadam AS; Miller LVC; Smith AE; Vaysburd M; Sakya SA; Sanford S; Keeling S; Tuck BJ; Katsinelos T; Green C; Skov L; Kaalund SS; Foss S; Mayes K; O'Connell K; Wing M; Knox C; Banbury J; Avezov E; Rowe JB; Goedert M; Andersen JT; James LC; McEwan WA
Science; 2023 Mar; 379(6639):1336-1341. PubMed ID: 36996217
[TBL] [Abstract][Full Text] [Related]
2. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.
McEwan WA; Falcon B; Vaysburd M; Clift D; Oblak AL; Ghetti B; Goedert M; James LC
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):574-579. PubMed ID: 28049840
[TBL] [Abstract][Full Text] [Related]
3. Multiple Roles of TRIM21 in Virus Infection.
Li X; Yang L; Chen S; Zheng J; Zhang H; Ren L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675197
[TBL] [Abstract][Full Text] [Related]
4. The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21.
Kiss L; James LC
Semin Cell Dev Biol; 2022 Jun; 126():99-107. PubMed ID: 34823983
[TBL] [Abstract][Full Text] [Related]
5. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity.
Foss S; Watkinson R; Sandlie I; James LC; Andersen JT
Immunol Rev; 2015 Nov; 268(1):328-39. PubMed ID: 26497531
[TBL] [Abstract][Full Text] [Related]
6. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
7. [Passive Tau immunotherapy for prevention of Tau pathology progression].
Ozmen L; Collin L
Med Sci (Paris); 2015 Feb; 31(2):132-4. PubMed ID: 25744257
[No Abstract] [Full Text] [Related]
8. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
9. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
[TBL] [Abstract][Full Text] [Related]
10. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
[TBL] [Abstract][Full Text] [Related]
12. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
14. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
16. Cytosolic Internalization of Anti-DNA Antibodies by Human Monocytes Induces Production of Pro-inflammatory Cytokines Independently of the Tripartite Motif-Containing 21 (TRIM21)-Mediated Pathway.
Park H; Kim M; Seo Y; Ham Y; Cho MY; Kwon MH
Front Immunol; 2018; 9():2019. PubMed ID: 30233598
[TBL] [Abstract][Full Text] [Related]
17. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
18. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
19. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
20. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.
d'Abramo C; Acker CM; Schachter JB; Terracina G; Wang X; Forest SK; Davies P
Neurobiol Aging; 2016 Jan; 37():58-65. PubMed ID: 26508157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
